Quick Answer
Allogene Therapeutics, Inc. reported Research And Development Expense of $150.15 million for the year ending 2025.
- Allogene Therapeutics, Inc. showed a decrease of -21.9% in Research And Development Expense from 2024 to 2025.
- This data is from Allogene Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Historical annual values: Fiscal year 2025: $150.15 million | Fiscal year 2024: $192.30 million | Fiscal year 2023: $242.91 million | Fiscal year 2022: $256.39 million | Fiscal year 2021: $220.18 million | Fiscal year 2020: $192.99 million | Fiscal year 2019: $144.54 million | Fiscal year 2018: $151.86 million | Fiscal year 2017: $0.00.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: